Shattuck Labs, Inc. (STTK), a biotechnology company specializing in autoimmune and inflammatory diseases, Thursday shared promising preclinical data from its GLP toxicology study of SL-325, a high-affinity DR3 blocking antibody, at the 20th Congress of the European Crohn's and Colitis Organization or ECCO.
The study in non-human primates showed no toxicity or residual agonism at doses up to 100 mg/kg, confirming the drug's safety profile.
Additionally, SL-325 demonstrated durable DR3 receptor occupancy and no evidence of T-cell activation or Treg proliferation, supporting its potential for extended dosing intervals in humans.
Shattuck plans to file an IND application for SL-325 in the third quarter of 2025, with Phase 1 trials set to begin later this year.
CEO Taylor Schreiber highlighted the significance of these results, which reinforce SL-325's potential as a breakthrough treatment for inflammatory bowel disease or IBD.
Currently, STTK is trading at $1.27, up by 0.80 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.